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Receptors for mineralocorticoid hormones are expressed in myocardial cells and evidence
obtained in animal studies suggests that activation of these receptors causes cardiac dam-
age independent from blood pressure levels. In the last years, many of the issues related
to the effects of aldosterone on the heart have received convincing answers and clinical
investigation has focused on a variety of conditions including systolic and diastolic heart fail-
ure, arrhythmia, primary hypertension, and primary aldosteronism. Some issues, however,
await clarification in order to obtain better understanding of what could be the role of aldos-
terone blockade in prevention and treatment of cardiovascular diseases. In this article, we
overview the most recent findings of animal studies that have examined the contribution of
aldosterone to cardiac function and clinical studies that have investigated the influence of
aldosterone on left ventricular structure and function in the setting of primary hypertension
and primary aldosteronism.
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INTRODUCTION
Aldosterone is an hormone secreted by the outermost portion of
the adrenal cortex and participates to regulation of blood pres-
sure by exerting its main effects on the distal nephron. At this
site, aldosterone increases sodium and water reabsorption leading
to expansion of the extracellular fluid volume. New experimental
and clinical evidence that has emerged in the last decade indicates
that, in addition to the actions on the kidney and contribution to
body fluid and electrolyte balance, aldosterone affects many cell
types where it regulates a variety of signal transduction mecha-
nisms and cellular responses, the most relevant of which might
result in tissue inflammation, hypertrophy, and fibrosis.
Expression of receptors for mineralocorticoid hormones (MR)
has been detected in human cardiomyocytes and cardiac fibrob-
lasts (1) and their protracted exposure to elevated circulating
levels of aldosterone leads to myocardial damage that is unre-
lated to blood pressure changes (2). In fact, continuous infusion
of aldosterone plus saline load in rodents causes inflammatory
changes of the myocardium (3) that, in the long-term, result in
tissue fibrosis (4). Also, and most important, myocardial fibro-
sis in these animal models of chronic aldosterone infusion is
prevented by bilateral adrenalectomy or administration of MR
blockers (5).
It is now more than a decade since two landmark clinical
studies that investigated the effects of aldosterone antagonists in
patients with advanced stages of cardiac insufficiency were pub-
lished, reporting significantly decreased mortality with use of these
drugs on top of standard treatment. The RALES study (6) was con-
ducted in patients with New York Heart Association (NYHA) class
III–IV heart failure who were treated with spironolactone and the
EPHESUS study (7) in patients with myocardial infarction asso-
ciated with severe left ventricular dysfunction who were treated
with eplerenone, a MR antagonist without cross-reactivity with
the receptor for androgens and progesterone. Later on, evidence
of beneficial effects of aldosterone antagonists was extended to
patients with earlier stages of heart failure in the EMPHASIS-HF
study (8). In this trial, patients with NYHA class II cardiac fail-
ure and left ventricular ejection fraction of 35% or less received
up to 50 mg/day of eplerenone in addition to standard treat-
ment. The study was interrupted after a follow-up of <2 years
because the composite cardiovascular outcome (cardiovascular
death and hospitalization for heart failure) was 37% less frequent
in patients who were treated with eplerenone than in those who
had placebo. Taken together, these studies on systolic heart failure
conveyed the information that blockade of the effects of aldos-
terone acts beneficially on the heart and provided convincing
clinical evidence of the untoward effects of the hormone. Recent
observations obtained in rodents models indicate that the car-
diotoxic effects of aldosterone are mediated by oxidative activation
of multifunctional Ca(2+)/calmodulin-dependent protein kinase
II causing cardiac rupture and increased mortality after myocardial
infarction (9).
Some issues related to the cardiac effects of aldosterone have
found appropriate explanations during the last two decades. It
has become clear that inappropriately high-aldosterone levels
could induce myocardial damage and investigation on the interac-
tion between aldosterone and the cardiovascular system has been
expanded beyond systolic heart failure to other clinical conditions
such as diastolic heart failure, arrhythmia, primary hypertension,
and primary aldosteronism. Other issues,however,need better def-
inition and the possible role of aldosterone blockade in prevention
and treatment of cardiac conditions needs further investigation.
This review summarizes the latest findings obtained in preclinical
animal and human studies that have examined the impact of cir-
culating aldosterone and MR activation on cardiac structure and
function in hypertension.
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ALDOSTERONE AND THE HEART: ANIMAL STUDIES
As stated above, high-affinity MR have been detected in car-
diac myocytes and fibroblasts (1) and their activation can induce
myocardial damage with mechanisms that are independent of
blood pressure elevation (2). Landmark experiments demon-
strated that chronic aldosterone infusion caused fibrosis in the
heart of rats that were fed a high-salt containing diet (4). In a
subsequent series of elegant experiments, Rocha et al. demon-
strated that inflammation of the perivascular tissue is antecedent
to aldosterone-induced myocardial fibrosis (3) and that both
inflammation and fibrosis can be effectively prevented by removal
of the adrenal glands or, alternatively, by administration of aldos-
terone antagonists (5). Inappropriate elevation of aldosterone has
been shown to lead to development of myocardial changes and
the related cardiac dysfunction through a variety of mechanisms,
including activation of oxidative stress (10, 11). In agreement with
these observations, the beneficial effects on myocardial fibrosis of
aldosterone antagonists (12) have been associated with a reduc-
tion of oxidative stress at the level of cardiomyocytes (13) and
further evidence has been obtained in experiments conducted in
genetically manipulated models.
Ventricular remodeling was investigated in mice with spe-
cific inactivation of cardiomyocyte MR [MR(MLCCre)] after an
experimentally induced myocardial infarction (14). In these mice,
cardiac structure and function were assessed 8 weeks after liga-
tion of a coronary artery with evidence that ventricular dilatation
and systolic dysfunction were significantly attenuated as com-
pared to control mice. Preservation of ventricular volume and
systolic function in mice with inactivated MR was associated
with decreased generation of reactive oxygen species and better
neovascularization of the infarcted area. In another study on a
murine transgenic model [(mRen2)27 rat] characterized by per-
sistent increase of tissue angiotensin-II and circulating aldosterone
levels (15), it was reported that blockade of MR improves cardiac
function. These transgenic animals had increased blood pressure
and cardiac abnormalities consisting of impaired diastolic relax-
ation associated with ventricular hypertrophy and fibrosis and
were treated with either hypotensive or non-hypotensive doses of
spironolactone for 3 weeks that were compared with placebo. Non-
invasive examination of the hearts demonstrated that both doses of
spironolactone improved left ventricular diastolic function. Also,
rats that were treated with placebo had evidence of increased
generation of reactive oxygen species and increased biochemical
markers of fibrosis that was not present in rats that received both
doses of aldosterone antagonist. In summary, available evidence
obtained in animal models with use of aldosterone antagonists or
genetic manipulation of the MR indicates that aldosterone and its
receptors contribute to both systolic and diastolic myocardial dys-
function with mechanisms that are tightly related to induction of
oxidative stress. In addition to its impact on myocardial structure
and function, aldosterone induces electrophysiological rearrange-
ment of cardiomyocytes that are caused by changes in sarcolemmal
ion transport systems and might explain the proarrhythmic effects
of the hormone (16, 17).
In addition to direct effects on the myocardium, untoward
effects of aldosterone on the heart could result from actions of
the hormone on arterial vessels and, in particular, on the coronary
arteries. Excess hypertrophy (18) and fibrosis (19) of the aorta
were reported in hypertensive rat models with high-circulating
aldosterone levels and it was demonstrated that vascular remodel-
ing and fibrosis of hypertensive animals could be corrected by
administration of eplerenone (20). Also, and most important,
expression of MR was detected in vascular smooth muscle and
endothelial cells obtained from human coronary arteries (21),
suggesting that aldosterone might be involved in regulation of
coronary flow. In support of this possibility, recent studies have
reported the involvement of aldosterone and the MR in regulation
of vascular tone. First, increased vascular response to a variety
of vasoconstrictors has been demonstrated in genetically manip-
ulated mice that over express the MR in endothelial cells (22).
Second, aldosterone decreases the activity of the BKCa potas-
sium channel that is associated with coronary smooth muscle
cells (23) and is involved in regulation of coronary functional
reserve. Third, investigation of the endothelium-dependent coro-
nary responses in genetically manipulated mice that over express
the MR has shown that acetylcholine-induced vasodilation of
coronary arteries is significantly impaired (24). Of great relevance
is the fact that in these mice impaired endothelium-dependent
coronary vasodilation was prevented by treatment with either
aldosterone antagonists or antioxidants, once again suggesting that
increased generation of reactive oxygen species mediates the effects
of aldosterone and MR activation on the heart and vessels.
ALDOSTERONE AND LEFT VENTRICULAR CHANGES IN
PRIMARY HYPERTENSION
Substantial clinical evidence indicates that left ventricular hyper-
trophy is associated with increased cardiovascular risk in hyperten-
sive patients (25) and that antihypertensive treatments that lead to
regression of hypertrophy decrease such risks (26). Therefore, it is
important to understand whether aldosterone and MR-mediated
mechanisms could contribute to ventricular hypertrophy and the
related cardiac functional changes in primary hypertension. Many
clinical studies reported a specific ability of renin–angiotensin
system (RAS) blockers in causing regression of hypertension-
induced left ventricular hypertrophy (27, 28). However, a sig-
nificant proportion of patients with high-blood pressure and
ventricular hypertrophy who are treated with either angiotensin-
converting enzyme inhibitors or angiotensin-receptor blockers do
not have their ventricular mass reduced by treatment. This might
be explained, at least in part, by an “escape” of aldosterone pro-
duction from the inhibitory effect of these drugs (29) and this
possibility received support from a study that reported that left
ventricular mass decreases with use of RAS blockers only in those
hypertensive patients who had persistent decrease in plasma aldos-
terone levels (30). In agreement with this observation, two studies
(31, 32) that were conducted in hypertensive patients with left
ventricular hypertrophy showed that addition of MR antagonists
to RAS blockers increased significantly the extent of ventricular
mass reduction obtained with treatment, despite no significant
difference was observed in blood pressure changes. The 4-E study
was designed to compare the effects of enalapril, eplerenone, or
the combination of the two drugs on hypertension-related left
ventricular hypertrophy (33). After 9 months, decrease of ven-
tricular mass was comparable in patients treated with enalapril
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or eplerenone, and the combination of the two drugs had sig-
nificantly greater effects on left ventricular mass reduction than
those obtained with each single drug. Another study conducted
in hypertensive patients with left ventricular diastolic dysfunc-
tion demonstrated that low-dose spironolactone (25 mg/day) was
more effective than placebo in restoring normal diastolic func-
tion (34). Finally, in a study of hypertensive patients who were
unresponsive to the combination of three antihypertensive drugs,
spironolactone (25–50 mg/day) was added to the ongoing treat-
ment (35). In this study, spironolactone decreased significantly
blood pressure and left ventricular mass with an extent of ven-
tricular mass reduction that tended to be greater in patients with
elevated pre-treatment plasma aldosterone levels.
As stated above, knowledge of possible contribution of aldos-
terone and MR-mediated mechanisms to the development and
progression of hypertensive ventricular hypertrophy is relevant
because hypertrophy is an important predictor of major cardio-
vascular events. Current evidence was principally obtained with
use of MR antagonists and strongly supports a role for aldosterone
as a determinant of left ventricular hypertrophy and diastolic dys-
function in primary hypertension, with important implications
for treatment of these conditions. It is also important to notice
that beneficial effects of MR antagonists on left ventricular struc-
ture and function could be relevant not only in patients with
elevated plasma aldosterone but also in patients without evidence
of aldosterone excess (36).
ALDOSTERONE AND LEFT VENTRICULAR CHANGES IN
PRIMARY ALDOSTERONISM
Primary aldosteronism is an endocrine disorder that is associated
with hypertension, hypokalemia, metabolic alkalosis, suppressed
plasma renin, and inappropriately elevated aldosterone secretion
that is caused by an adrenal adenoma or bilateral adrenal hyper-
plasia. Early descriptions of patients with primary aldosteronism
reported a low incidence of cardiovascular complications (37) that
was generally explained by suppression of circulating angiotensin-
II as a result of extracellular fluid volume expansion (38). More
recent views, however, clearly indicate that long-term exposure
to elevated circulating aldosterone results in substantial cardiac
damage that occurs independent of the blood pressure levels (39,
40). Primary aldosteronism offers a unique clinical setting to
investigate the effects of aldosterone on target organs because, in
this condition, the effects of aldosterone are isolated from those
of the RAS.
It is well known that abnormalities of the heart are common
sequelae of hypertensive states and have been detected also in
patients with primary aldosteronism. In fact, the majority of car-
diac ultrasound evaluations conducted in patients with primary
aldosteronism have found significantly greater left ventricular
mass than in other types of hypertension (40, 41). In primary
aldosteronism, increased frequency of inappropriately elevated
ventricular mass has been reported also in the absence of left
ventricular hypertrophy (42), suggesting that protracted exposure
to high-aldosterone levels increases the ventricular mass beyond
what is needed to compensate for the hypertension-related cardiac
load. While left ventricular systolic function in primary aldostero-
nism does not generally differ from other types of hypertensive
disease, an abnormal pattern of left ventricular filling is com-
monly detected, indicating diastolic dysfunction (43, 44). Abnor-
mal filling has been associated with abnormalities of ultrasound
densitometric patterns of the left ventricle (43), suggesting tissue
fibrosis.
In addition to findings of cross-sectional studies, substantial
information on the effects of aldosterone on the heart of patients
with primary aldosteronism could be obtained from investigations
conducted after treatment of this endocrine disorder. Most of these
studies were short-term echocardiographic evaluations of patients
who underwent unilateral adrenalectomy that reported normal-
ization of left ventricular mass and diastolic filling properties
(43, 44). In a first prospective, long-term follow-up, echocardio-
graphic study of patients with primary aldosteronism who were
treated with either surgery or spironolactone, we found com-
parable reduction of left ventricular mass, although this change
occurred more rapidly in adrenalectomized patients (45). Notably,
the extent of change in ventricular mass obtained with both treat-
ments was directly related with pre-treatment plasma aldosterone
levels (41). Later on, other studies have retrospectively analyzed
the long-term cardiac outcome of surgical and medical treatment
of primary aldosteronism reporting conflicting results (46–48).
In fact, while adrenalectomy was almost consistently found to
rapidly decrease left ventricular mass, effects of treatment with MR
antagonists were inconsistent. Among other factors, differences
in findings might be related to different duration of follow-up,
inasmuch as reduction of left ventricular mass might require
longer time to occur in patients treated with MR antagonists than
surgery. Thus, effects of medical treatment of primary aldostero-
nism on ventricular mass remain controversial and this issue will
be worthy of further evaluation in cumulative analyses that could
increase the statistical power of each of these studies taken sepa-
rately. In a recent study, patients with an aldosterone-producing
adenoma associated with somatic mutations in the KCNJ5 potas-
sium channel have been compared with patients without such
mutations (49). Despite blood pressure levels and need for anti-
hypertensive medications were comparable between patients with
and without the KCNJ5 mutation, the former group had signifi-
cantly greater plasma aldosterone levels and left ventricular mass.
Surgical removal of adenoma in these patients, however, induced
significant and comparable decrease in ventricular mass in patients
with and without the potassium channel mutation. This obser-
vation suggests that differences in mechanisms that underlie the
development of adrenal adenoma might affect the degree of car-
diac involvement in primary aldosteronism, but not the possible
benefits of treatment.
In summary, the evidence supporting a role of aldosterone in
the development of cardiac hypertrophy that overtakes that of
high-blood pressure itself is strong. As shown in many studies (50–
53), patients with primary aldosteronism have greater frequency
of coronary heart and cerebrovascular disease, congestive heart
failure, and atrial fibrillation than matched patients with primary
hypertension. Due to the relevance of ventricular hypertrophy in
the assessment of cardiovascular risk, its regression might result in
substantial protection from cardiovascular events even in patients
with primary aldosteronism. This issue will have to be further
investigated in adequately designed protocols.
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CONCLUSION
Robust experimental and clinical evidence indicates that aldos-
terone can cause myocardial tissue damage, including hypertro-
phy and fibrosis over that induced by high-blood pressure itself.
Increased generation of reactive oxygen species appears to have a
major role in most of the consequences on the cardiovascular sys-
tem of aldosterone elevation and MR activation. Both in primary
hypertension and hyperaldosteronism, aldosterone contributes to
development and progression of left ventricular hypertrophy and
thereby to cardiovascular risk. Therefore, MR antagonists could
be beneficial in hypertensive states in terms of reduction of left
ventricular mass and improvement of cardiovascular outcome.
Although the important progress witnessed during the last years
has contributed substantially to clarify many issues related to the
effects of aldosterone and the heart, many others still await sat-
isfactory answers. Further studies will be needed to address these
issues and to explore the potential benefits of aldosterone blockade
on the cardiovascular system.
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